On #InterstitialLungDiseaseDay, we stand with patients, caregivers, and the entire ILD community. At Mediar Therapeutics, we are committed to developing transformative treatments for both Idiopathic Pulmonary Fibrosis (IPF) and Systemic Sclerosis (SSc)—two diseases that cause significant lung scarring and progressive interstitial lung disease. Our approach to target myofibroblasts, key drivers of fibrosis, aims to address the underlying cause of these conditions. Together, we work toward a future where patients can breathe easier and live fuller lives. #ILD #IPF #SSc #Fibrosis #LungHealth #PulmonaryFibrosis #ResearchInnovation #BreathOfHope
Mediar Therapeutics
Biotechnology Research
Boston, Massachusetts 2,624 followers
Mediar Therapeutics is a preclinical stage biotech company developing medicines to halt, or even reverse, fibrosis.
About us
Mediar Therapeutics is a biotechnology company pioneering a new approach to fibrosis treatment that halts the disease at a different source – the fibrotic mediators that drive disease progression. Mediar was founded based on a deep understanding of the complex science underlying fibrosis onset and progression. By combining novel targets with reliable, easily detectable blood biomarkers and familiar modalities, Mediar is derisking the path forward for fibrosis therapies in clinical development. For more information, contact info@mediartx.com
- Website
-
http://www.mediartx.com
External link for Mediar Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2019
Locations
-
Primary
20 Overland St
Boston, Massachusetts 02215, US
Employees at Mediar Therapeutics
-
Michael Baran
Partner - Pfizer Ventures
-
Daniel Beal, RN, BSN, MBA
Director, Clinical Trial Lead at Mediar Therapeutics | MBA, Clinical Research Project Management Professional
-
Rohan Manohar
Translational Sciences / Fibrosis / IPF / Systemic Sclerosis
-
Andreas Jurgeit
Partner at Gimv
Updates
-
As Pulmonary Fibrosis Awareness Month progresses, we reflect on the momentum we’ve built in our pursuit of innovative #fibrosis treatments. Our recently initiated #clinical trials, representative of our commitment to changing the future for those living with this challenging condition, are testing therapies that specifically target the cellular mechanisms driving fibrosis. We’re exploring uncharted territory in fibrosis treatment, with the goal of not only halting progression but potentially reversing damage. While there’s still much work ahead, each step brings us closer to providing patients with the hope and solutions they deserve. Thank you to our dedicated team and partners for their unwavering commitment to our mission. #PulmonaryFibrosisAwareness #FightFibrosis #PFF #PFAM
-
We have four more reasons to celebrate this month: Happy anniversary to Mediarities Colleen Graham, MBA, Michael Cain, MS, Max Leabo and Lin Ji, MS! Your passion and diligence are truly inspiring, and play a crucial role in helping us achieve our goals. Thank you for your exceptional contributions and for continually striving to go above and beyond in our work to transform the treatment of #fibrosis. #TeamAnniversaries #WorkMilestones #EmployeeAppreciation #CompanyCulture #biotech
-
⭐ This Pulmonary Fibrosis Awareness Month, we’re united in the fight against #fibrosis! ⭐ At Mediar, we’re committed to developing innovative treatments to combat fibrosis and improve the lives of those affected by this challenging condition. Pulmonary fibrosis affects over 200,000 people in the U.S. alone, causing scarring in the lungs and making it difficult to breathe. We’re proud to support the Pulmonary Fibrosis Foundation in its mission to raise awareness and drive research. Join us during Pulmonary Fibrosis Awareness Month as we stand with the PF community, share stories, and highlight the urgent need for continued research and support. #PulmonaryFibrosisAwareness #FightFibrosis #PFF #PFAM
-
This week, Mediar is at the 8th Annual IPF Summit in our hometown Boston, where our Chief Medical Officer Jeffrey Bornstein, MD and Clinical Advisory Board Member Toby Maher, MD, PhD, Professor of Clinical Medicine & Director of Interstitial Lung Disease at The University of Southern California, will participate in a panel discussion. “Innovative Strategies to Mitigate the Competitive & Challenging Nature of Clinical Trials in High-Risk Rare Diseases” will highlight recruiting patients in rare disease populations, digital health technology for remote monitoring, and improving efficacy and efficiency of clinical trials. To join us on Tuesday August 20 at 2:30 pm, register here: https://lnkd.in/ezEyYMs #fibrosis #biotech #IPF2024
-
This month we celebrate the work anniversaries of three team members who bring dedication, talent, and passion to our organization every day. 🎊 Chelsea Duncan, Ruoyu Zhuo, and William Feeney, thank you for being an essential part of our journey as we fearlessly chart a different course toward patient impact in the treatment of #fibrosis. We appreciate all you do to make our company thrive! 🙌 #TeamAnniversaries #WorkMilestones #EmployeeAppreciation #CompanyCulture #biotech
-
Mediar is thrilled to share we have initiated our second clinical program in our portfolio of novel first-in-class antibodies designed to halt fibrosis and received both orphan drug and fast track designations for MTX-463, our anti-WISP program in a separate Ph-1 study: two pivotal milestones in our pursuit to fulfill the significant gap in #fibrosis treatment. By targeting the myofibroblast - the key pathogenic cell in fibrosis that drives scarring, disease progression and organ failure - we aim to bring forward novel anti-fibrotic therapies that potentially have a precision medicine approach. Read more here: https://lnkd.in/gM2pqQEy #Biotech
-
Today marks a very special milestone at Mediar Therapeutics: Our first employee and CSO leader, Paul Yaworsky, PhD, is celebrating his 5th year! 🎊 Paul, your scientific acumen, unwavering dedication, and infectious enthusiasm have been paramount to Mediar’s ability to advance a novel fibrosis portfolio into the clinic. You inspire us to go above and beyond to realize our mission for patient impact in the treatment of #fibrosis. Here’s to many more years of success! #TeamAnniversaries #WorkMilestones #EmployeeAppreciation #CompanyCulture #biotech
-
Cheers to Timothy Kiprono and Jeffrey Bornstein, MD who are celebrating their anniversaries with Mediar! Your passion and expertise have made a remarkable impact on our workplace and our mission to pioneer a new path in #fibrosis treatment. Looking forward to many years to come! #CompanyCulture #biotech
-
Welcome Thendral Selvam, our Summer Co-Op graduate student majoring in biotechnology at Northeastern University. Fun fact: Thendral is a foodie who loves cooking – noting she finds it a relaxing and delicious way to express her creativity – as well as exploring different restaurants and cafes. We’re excited to have you on board for an enriching, immersive experience in #biotech. #fibrosis #CompanyCulture